Citigroup’s LYRA THERAPEUTICS INC LYRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3
| Closed | -$9 | – | 6202 |
|
|
2025
Q4 | $9 | Sell |
3
-702
| -100% | -$3.49K | ﹤0.01% | 5818 |
|
|
2025
Q3 | $4.65K | Sell |
705
-90
| -11% | -$660 | ﹤0.01% | 5251 |
|
|
2025
Q2 | $7.12K | Buy |
795
+91
| +13% | +$755 | ﹤0.01% | 5237 |
|
|
2025
Q1 | $4.44K | Sell |
704
-58
| -8% | -$542 | ﹤0.01% | 5291 |
|
|
2024
Q4 | $7.86K | Buy |
762
+61
| +9% | +$671 | ﹤0.01% | 5414 |
|
|
2024
Q3 | $9K | Buy |
701
+488
| +229% | +$7.17K | ﹤0.01% | 5301 |
|
|
2024
Q2 | $2.95K | Sell |
213
-2,165
| -91% | -$245K | ﹤0.01% | 5304 |
|
|
2024
Q1 | $739K | Sell |
2,378
-111
| -4% | -$29.6K | ﹤0.01% | 3268 |
|
|
2023
Q4 | $652K | Buy |
2,489
+1,135
| +84% | +$205K | ﹤0.01% | 3201 |
|
|
2023
Q3 | $265K | Buy |
+1,354
| New | +$242K | ﹤0.01% | 3497 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 6083 |
|
|
2021
Q2 | $0 | Sell |
1
-12
| -92% | -$5.47K | ﹤0.01% | 6284 |
|
|
2021
Q1 | $8K | Sell |
13
-12
| -48% | -$7.5K | ﹤0.01% | 5760 |
|
|
2020
Q4 | $14K | Buy |
25
+17
| +213% | +$9.58K | ﹤0.01% | 6830 |
|
|
2020
Q3 | $4K | Sell |
8
-6
| -43% | -$3.73K | ﹤0.01% | 7124 |
|
|
2020
Q2 | $8K | Buy |
+14
| New | +$10.2K | ﹤0.01% | 7134 |
|
Other funds holding LYRA
Citigroup's LYRA Position: Q1 2026 in Review
Citigroup sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2026, closing a stake of 3 shares — an estimated $9 sold.
Citigroup first reported a position in LYRA in Q2 2020 and held it in 15 quarters. The position peaked at $739K in Q1 2024. 1 fund tracked by Wall St. Rank holds LYRA as of Q1 2026.
- Citigroup reported no remaining LYRA THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
- Citigroup sold 3 LYRA THERAPEUTICS INC shares in Q1 2026, an estimated $9.
- Citigroup first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 15 quarters.
- Citigroup's LYRA THERAPEUTICS INC position peaked at $739K in Q1 2024.
- 1 fund tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.